Osimertinib (Tagrisso, AstraZeneca), continues to provide an overall survival (OS) benefit after definitive chemoradiotherapy (CRT) in patients with unresectable stage III epidermal growth factor ...
PARIS — Final overall survival results from the phase 3 MARIPOSA study showed that the first-line amivantamab plus lazertinib combination extended overall survival notably more than osimertinib ...
Per independent review, the median progression-free survival was 7.5 months. Combining savolitinib with osimertinib can reverse osimertinib resistance in patients with advanced, EGFR-mutant non ...
Researchers conducted an exploratory analysis of 220 patients from ADAURA, including 112 who received osimertinib and 108 who received placebo. MRD was assessed using tumour-informed circulating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback